CMS Establishes Coding Validating Sensus SRT for Treating Non-Melanoma Skin Cancer
First-ever dedicated Current Procedural Terminology (CPT®) codes represent compelling economics and reimbursement certainty
BOCA RATON, Fla.–(BUSINESS WIRE)–Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological skin conditions, announces that the Centers for Medicare & Medicaid Services (CMS) has published a distinct set of treatment codes specific to the use of superficial radiotherapy (SRT and IG-SRT) for non-melanoma skin cancer (NMSC).
SRT-dedicated CPT codes reflect:
- CMS’ acknowledgement of SRT as a standalone treatment modality for NMSC.
- An increase in reimbursement per fraction of more than 300% compared with current treatment/fractionation codes, significantly enhancing physician economics.
- Strengthened reimbursement certainty, reinforcing physician and practice confidence in delivering non-invasive SRT therapies.
- Enhanced patient access and choice, enabling individuals diagnosed with NMSC to select SRT treatment with assurance of coverage and no ambiguity in payment.
“This announcement is a pivotal moment for SRT and one we have been working toward since Sensus was founded. Following the American Medical Association’s establishment of dedicated CPT codes for superficial radiotherapy earlier this year, and CMS’s validation through their inclusion in the 2026 Physician Fee Schedule, we are empowered to expand access, support our physician partners and accelerate the adoption of our SRT platform for the benefit of patients seeking non-surgical treatment options” said Joe Sardano, Chief Executive Officer of Sensus Healthcare.
This coding update advances Sensus Healthcare’s strategy to broaden its commercial footprint in dermatology, radiation oncology and skin-cancer treatment settings and underscores the Company’s commitment to delivering innovative, patient-centric care.
About Sensus Healthcare
Sensus Healthcare, Inc. is a global pioneer in the development and delivery of non-invasive treatments for skin cancer and keloids. Leveraging its cutting-edge superficial radiotherapy (SRT and IG-SRT) technology, the company provides healthcare providers with a highly effective, patient-centric treatment platform. With a dedication to driving innovation in radiation oncology, Sensus Healthcare offers solutions that are safe, precise, and adaptable to a variety of clinical settings. For more information, please visit www.sensushealthcare.com.
Forward-Looking Statements
This press release includes statements that are, or may be deemed, ”forward-looking statements.” In some cases, these statements can be identified by the use of forward-looking terminology such as “believes,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “will,” “should,” “approximately,” “potential” or negative or other variations of those terms or comparable terminology, although not all forward-looking statements contain these words.
Forward-looking statements involve risks and uncertainties because they relate to events, developments, and circumstances relating to Sensus, our industry, and/or general economic or other conditions that may or may not occur in the future or may occur on longer or shorter timelines or to a greater or lesser degree than anticipated. In addition, even if future events, developments, and circumstances are consistent with the forward-looking statements contained in this press release, they may not be predictive of results or developments in future periods. Although we believe that we have a reasonable basis for each forward-looking statement contained in this press release, forward-looking statements are not guarantees of future performance, and our actual results of operations, financial condition and liquidity, and the development of the industry in which we operate may differ materially from the forward-looking statements contained in this press release, as a result of the following factors, among others: the possibility that inflationary pressures continue to impact our sales; the level and availability of government and/or third party payor reimbursement for clinical procedures using our products, and the willingness of healthcare providers to purchase our products if the level of reimbursement declines; concentration of our customers in the U.S. and China, including the concentration of sales to one particular customer in the U.S.; the development by others of new products, treatments, or technologies that render our technology partially or wholly obsolete; the regulatory requirements applicable to us and our competitors; our ability to efficiently manage our manufacturing processes and costs; the risks arising from doing business in China and other foreign countries; legislation, regulation, or other governmental action that affects our products, taxes, international trade regulation, or other aspects of our business; the performance of the Company’s information technology systems and its ability to maintain data security; our ability to obtain and maintain the intellectual property needed to adequately protect our products, and our ability to avoid infringing or otherwise violating the intellectual property rights of third parties; and other risks described from time to time in our filings with the Securities and Exchange Commission, including our Annual Reports on Form 10-K and Quarterly Reports on Form 10-Q.
Any forward-looking statements that we make in this press release speak only as of the date of such statement, and we undertake no obligation to update such statements to reflect events or circumstances after the date of this press release, except as may be required by applicable law. You should read carefully our “Introductory Note Regarding Forward-Looking Information” and the factors described in the “Risk Factors” section of our periodic reports filed with the Securities and Exchange Commission to better understand the risks and uncertainties inherent in our business.
View source version on businesswire.com: https://www.businesswire.com/news/home/20251104697828/en/
Contact:
Alliance Advisors IR
Tirth T. Patel
[email protected]
212-201-6614
KEYWORDS: Florida United States North America
INDUSTRY KEYWORDS: Health Oncology Other Health Medical Devices
MEDIA: